Calithera Biosciences Statistics
Total Valuation
Calithera Biosciences has a market cap or net worth of 487.
| Market Cap | 487 |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Calithera Biosciences has 4.87 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 4.87M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.10% |
| Owned by Insiders (%) | 0.93% |
| Owned by Institutions (%) | 0.00% |
| Float | 4.83M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.60, with a Debt / Equity ratio of 0.08.
| Current Ratio | 3.60 |
| Quick Ratio | 3.44 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.04 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -114.14% and return on invested capital (ROIC) is -70.90%.
| Return on Equity (ROE) | -114.14% |
| Return on Assets (ROA) | -56.29% |
| Return on Capital (ROIC) | -70.90% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -2.37M |
| Employee Count | 9 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -96.80% in the last 52 weeks. The beta is -0.35, so Calithera Biosciences's price volatility has been lower than the market average.
| Beta (5Y) | -0.35 |
| 52-Week Price Change | -96.80% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.01 |
| Relative Strength Index (RSI) | 38.48 |
| Average Volume (20 Days) | 1,205 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.93 |
Income Statement
| Revenue | n/a |
| Gross Profit | -28.53M |
| Operating Income | -42.07M |
| Pretax Income | -39.65M |
| Net Income | -21.29M |
| EBITDA | -41.82M |
| EBIT | -42.07M |
| Earnings Per Share (EPS) | -7.94 |
Balance Sheet
The company has 25.45 million in cash and 1.67 million in debt, giving a net cash position of 23.79 million or 4.88 per share.
| Cash & Cash Equivalents | 25.45M |
| Total Debt | 1.67M |
| Net Cash | 23.79M |
| Net Cash Per Share | 4.88 |
| Equity (Book Value) | 20.39M |
| Book Value Per Share | -0.40 |
| Working Capital | 19.23M |
Cash Flow
In the last 12 months, operating cash flow was -43.61 million and capital expenditures -133,000, giving a free cash flow of -43.74 million.
| Operating Cash Flow | -43.61M |
| Capital Expenditures | -133,000 |
| Free Cash Flow | -43.74M |
| FCF Per Share | -8.98 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Calithera Biosciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -35.17% |
| Shareholder Yield | -35.17% |
| Earnings Yield | -7,942,708.00% |
| FCF Yield | -8,977,122.00% |
Stock Splits
The last stock split was on June 15, 2022. It was a reverse split with a ratio of 0.05.
| Last Split Date | Jun 15, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.05 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |